← back to search

Paul Brunetta

University of California, San Francisco · US
Area of research
Rheumatology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Systemic Lupus Erythematosus Research, Vasculitis and related conditions, Systemic Sclerosis and Related Diseases, and Otitis Media and Relapsing Polychondritis.
h-index
26
citations
9,457
works
60
NIH funding
primary concept
email

Recent publications

Initial Evaluation of Acceptability, Engagement, and Effectiveness of the MO App to Provide Tailored and Comprehensive Support for Smoking Cessation: Development and Usability Study
JMIR mhealth and uhealth 2024cited by 7position: middledoi
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Arthritis & Rheumatology 2022cited by 22position: middledoi
Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant
American Journal of Transplantation 2019cited by 79position: middledoi
Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Arthritis & Rheumatology 2019cited by 36position: middledoi
Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis
Clinical Journal of the American Society of Nephrology 2018cited by 181position: lastdoi
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Arthritis & Rheumatology 2018cited by 66position: middledoi
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis
Lara D. Veeken 2017cited by 28position: middledoi
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis
Annals of the Rheumatic Diseases 2016cited by 229position: middledoi
ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap
Kidney International Reports 2016cited by 1position: middledoi
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type
Annals of the Rheumatic Diseases 2015cited by 261position: middledoi
Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement
Journal of the American Society of Nephrology 2014cited by 177position: middledoi
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
New England Journal of Medicine 2013cited by 726position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Philip Seo · Johns Hopkins University6 papers (2014–2022)Robert Spiera · Hospital for Special Surgery6 papers (2014–2022)Ulrich Specks · Mayo Clinic6 papers (2014–2022)E. William St. Clair · Duke University6 papers (2014–2022)Carol A. Langford · Cleveland Clinic6 papers (2014–2022)John H. Stone · Harvard University5 papers (2016–2022)Fernando C. Fervenza · The Ohio State University Wexner Medical Center5 papers (2014–2022)Paul A. Monach · Boston University5 papers (2015–2022)Peter A. Merkel · University of the Sciences5 papers (2014–2022)Gary S. Hoffman · McMaster University5 papers (2014–2019)Cees G. M. Kallenberg · University of Groningen5 papers (2014–2022)Matthew D. Cascino · United Therapeutics (United States)3 papers (2017–2019)Divi Cornec · Uppsala University3 papers (2017–2022)Linna Ding · National Institute of Allergy and Infectious Diseases2 papers (2014–2015) · 2 papers (2017–2018)Duvuru Geetha · Johns Hopkins University2 papers (2014–2019)Eli M. Miloslavsky · Twitter (United States)2 papers (2015–2016) · 2 papers (2017–2018)David Iklé · Rho (United States)2 papers (2014–2015)Hyon K. Choi · Boston University2 papers (2015–2016)